The first patient has been dosed in a Phase 1 investigator-initiated study led by MindMed (NASDAQ:MNMD; NEO:MMED) collaborator Prof. Dr. Matthias Liechti at University Hospital Basel to evaluate the effects of MDMA-like...
MindMed (NASDAQ:MNMD; NEO:MMED) announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), for the treatment of generalized...
Schond Greenway Mind Medicine (NASDAQ:MNMD; NEO:MMED) appointed Schond Greenway as CFO. He comes to MindMed with more than 20 years of experience in investment banking, finance and corporate advisory, and investment...
MindMed (NASDAQ:MNMD; NEO:MMED) is advancing a pipeline of psychedelic and next generation drug candidates to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology.
Mind Medicine (NASDAQ:MNMD; NEO:MMED) reported favorable safety and tolerability results from a Phase 1 placebo-controlled trial designed to assess safety, tolerability, pharmacokinetics and neurocognitive effects of MM...
Prof. Matthias Liechti and Dr. Friederike Holze, Mind Medicine’s (NASDAQ:MNMD; NEO:MMED) collaborators at University Hospital Basel presented positive topline data from a Phase 2 placebo-controlled investigator...